Cargando…

Clinical Applications of PSMA PET Examination in Patients with Prostate Cancer

SIMPLE SUMMARY: The prostate specific membrane antigens, abbreviated as PSMAs, are type II membrane proteins that are highly ex-pressed on the surface of malignant prostate tissue in prostate cancer (PCa), particularly in aggressive, andro-gen-deprived, metastatic, and hormone-refractory PCa. Today,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rasul, Sazan, Haug, Alexander R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367427/ https://www.ncbi.nlm.nih.gov/pubmed/35954432 http://dx.doi.org/10.3390/cancers14153768

Ejemplares similares

Clinical outcome of standardized (177)Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks
por: Rasul, Sazan, et al.
Publicado: (2019)

Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [(177)Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer
por: Stangl-Kremser, Judith, et al.
Publicado: (2021)

Clinical perspectives of PSMA PET/MRI for prostate cancer
por: Barbosa, Felipe de Galiza, et al.
Publicado: (2018)

Direct Patlak Reconstruction of [(68)Ga]Ga-PSMA PET for the Evaluation of Primary Prostate Cancer Prior Total Prostatectomy: Results of a Pilot Study
por: Rasul, Sazan, et al.
Publicado: (2023)

PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer
por: Combes, Alexander D., et al.
Publicado: (2022)

Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer
por: Cereser, Lorenzo, et al.
Publicado: (2023)

Response to [(177)Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases
por: Zisser, Lucia, et al.
Publicado: (2022)

PSMA PET in Imaging Prostate Cancer
por: Tsechelidis, Ioannis, et al.
Publicado: (2022)

Response and Toxicity to the Second Course of 3 Cycles of (177)Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Rasul, Sazan, et al.
Publicado: (2021)

Current role of PSMA-PET imaging in the clinical management of prostate cancer
por: Georgakopoulos, Alexander, et al.
Publicado: (2023)

Prediction of response and survival after standardized treatment with 7400 MBq (177)Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer
por: Rasul, Sazan, et al.
Publicado: (2020)

Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Wollenweber, Tim, et al.
Publicado: (2021)

FDG-PET Versus PSMA-PET: A Patient With Prostate Cancer
por: Kichloo, Asim, et al.
Publicado: (2020)

PSMA-PET in the early stages of prostate cancer
por: Barbosa, Felipe de Galiza
Publicado: (2023)

The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer
por: Kase, Adam M., et al.
Publicado: (2022)

Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET
por: Sabbagh, Ali, et al.
Publicado: (2022)

PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?
por: Urso, Luca, et al.
Publicado: (2023)

Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET
por: Leung, Kevin H., et al.
Publicado: (2022)

PSMA PET imaging in the diagnosis and management of prostate cancer
por: Houshmand, Sina, et al.
Publicado: (2023)

The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer—A Practical Clinical Review
por: Lisney, Anna Rebecca, et al.
Publicado: (2022)

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
por: Lenzo, Nat P., et al.
Publicado: (2018)

Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
por: Grubmüller, Bernhard, et al.
Publicado: (2018)

Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer
por: Kallur, Kumaraswamy G, et al.
Publicado: (2017)

Irreversible electroporation for prostate cancer using PSMA PET-CT
por: Shin, Dongho, et al.
Publicado: (2023)

Impact of ECG gating methods on the assessment of left ventricular cardiac function using PET/MRI
por: Rasul, Sazan, et al.
Publicado: (2022)

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
por: Rauscher, Isabel, et al.
Publicado: (2016)

Dual-Tracer PET-MRI-Derived Imaging Biomarkers for Prediction of Clinically Significant Prostate Cancer
por: Grubmüller, Bernhard, et al.
Publicado: (2023)

Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT
por: Karagiannis, Vasileios, et al.
Publicado: (2022)

The clinical application of (68)Ga-PSMA PET/CT and regulating mechanism of PSMA expression in patients with brain metastases of lung cancer
por: Pei, Yuchen, et al.
Publicado: (2023)

Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer
por: Galgano, Samuel J., et al.
Publicado: (2022)

The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making—The Urological Perspective
por: Hoffman, Azik, et al.
Publicado: (2023)

Accuracy of PET quantification in [(68)Ga]Ga-pentixafor PET/MR imaging of carotid plaques
por: Rausch, Ivo, et al.
Publicado: (2020)

DNA Damage in Blood Leukocytes of Prostate Cancer Patients Undergoing PET/CT Examinations with [(68)Ga]Ga-PSMA I&T
por: Schumann, Sarah, et al.
Publicado: (2020)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Comparison of (68)Ga-PSMA PET/CT and (18)F-PSMA PET/CT of a Patient with Prostate Cancer Recurrence on Urinary Bladder Wall
por: Soydal, Çiğdem, et al.
Publicado: (2023)

PSMA Receptor-Based PET-CT: The Basics and Current Status in Clinical and Research Applications
por: Adnan, Aadil, et al.
Publicado: (2023)

The added value of PSMA PET/MR radiomics for prostate cancer staging
por: Solari, Esteban Lucas, et al.
Publicado: (2021)

(68)Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer
por: Damjanovic, Jonathan, et al.
Publicado: (2019)

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status
por: Lütje, Susanne, et al.
Publicado: (2015)

Direct comparison of (99m)Tc-PSMA SPECT/CT and (68)Ga-PSMA PET/CT in patients with prostate cancer
por: Albalooshi, Batool, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k0h800jcgs8spkgcee7bdk1hvc